Menu
Search
|

Menu

Close
X

Ophthotech Corp OPHT.OQ (NASDAQ Stock Exchange Global Select Market)

2.65 USD
-0.09 (-3.28%)
As of Feb 22
chart
Previous Close 2.74
Open 2.74
Volume 55,596
3m Avg Volume 140,905
Today’s High 2.77
Today’s Low 2.63
52 Week High 4.60
52 Week Low 2.24
Shares Outstanding (mil) 35.94
Market Capitalization (mil) 92.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
210
FY16
51
FY15
52
EPS (USD)
FY17
3.422
FY16
-5.443
FY15
-3.046
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.96
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-73.71
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

David Guyer
Executive Chairman of the Board, Since 2017
Salary: $625,200.00
Bonus: $325,104.00
Glenn Sblendorio
President, Chief Executive Officer, Since 2017
Salary: $373,154.00
Bonus: $163,350.00
David Carroll
Chief Financial Officer, Senior Vice President, Treasurer, Since 2017
Salary: --
Bonus: --
Keith Westby
Chief Operating Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Barbara Wood
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: $404,620.00
Bonus: $129,478.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Penn Plz Fl 35
NEW YORK   NY   10119-0002

Phone: +1212.8458200

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

SPONSORED STORIES